Eterna Therapeutics is a preclinical-stage biopharmaceutical company focusing on realizing the potential of mRNA cell engineering to provide patients with new medicines. Co. has in-licensed a portfolio of over 100 patents covering primary mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system. Co. has a cell line customization and license agreement with Lineage Cell Therapeutics, Inc. (Lineage), pursuant to which, Lineage may request that Co. develops for, and deliver to, Lineage certain induced pluripotent stem cell lines. The ERNA stock yearly return is shown above.
The yearly return on the ERNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ERNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|